BioMarin to Attend Upcoming Conferences: Cowen Healthcare Conference, Credit Suisse Global Healthcare Conference and Barclays

BioMarin to Attend Upcoming Conferences: Cowen Healthcare Conference, Credit
Suisse Global Healthcare Conference and Barclays Global Healthcare Conference

SAN RAFAEL, Calif., Feb. 28, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Cowen
Healthcare Conference in Boston on March 4^th, the Credit Suisse Global
Healthcare Conference in London on March 6^th and the Barclays Global
Healthcare Conference in Miami on March 12^th.

Dan Maher, Senior Vice President of Product Development at BioMarin, will
present a company update at the Cowen Healthcare Conference on Monday, March
4, 2013 at 4:50 p.m. ET. Joshua Grass, Senior Vice President of Corporate and
Business Development at BioMarin, will present a company update at the
Barclays Global Healthcare Conference on Tuesday, March 12, at 8:30 a.m. ET.
Interested parties may access a live audio webcast of the conference call via
the investor section of the BioMarin website, www.BMRN.com. A replay of the
call will be archived on the site for at least one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme^® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme^® (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a
50/50 joint venture with Genzyme Corporation; Kuvan^® (sapropterin
dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership
with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and
Firdapse™ (amifampridine), which has been approved by the European Commission
for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product
candidates include BMN-110 (N-acetylgalactosamine 6-sulfatase), formally
referred to as GALNS, which successfully completed Phase 3 clinical
development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant
phenylalanine ammonia lyase), which is currently in Phase II clinical
development for the treatment of PKU, BMN-701, a novel fusion protein of
insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is
currently in Phase I/II clinical development for the treatment of Pompe
disease, BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is
currently in Phase I/II clinical development for the treatment of
genetically-defined cancers, and BMN-111, a modified C-natriuretic peptide,
which is currently in Phase I clinical development for the treatment of
achondroplasia. For additional information, please visit www.BMRN.com.
Information on BioMarin's website is not incorporated by reference into this
press release.

The BioMarin Pharmaceutical Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=11419

BioMarin^®, Naglazyme^®, Kuvan^® and Firdapse™ are registered trademarks of
BioMarin Pharmaceutical Inc.

Aldurazyme^® is a registered trademark of BioMarin/Genzyme LLC.

CONTACT: Investors:
         Eugenia Shen
         BioMarin Pharmaceutical Inc.
         (415) 506-6570
        
         Media:
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo